Fund holdings
16KShares reported · -56K vs prior quarter
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Loading…
GE HealthCare
GEHC · NASDAQ · Health Care Equipment
GEHC · NASDAQ · Health Care Equipment
Health Care Equipment company based in Chicago, Illinois.
Last close, Oct 1, 2026
$63.98
Adjusted for splits and dividends
Last 12 months
-15.3%
S&P 500 +14.3% over the same dates
Market value
$29.1B
Last close × shares outstanding
Bets against the stock: 16.9M shares sold short (3.7% of shares outstanding), -10.8% vs the previous count, 5.5 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
None
No open-market sales reported
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$20.6B
+4.8% vs the year before
Net income, fiscal 2025
$2.08B
As reported in the annual filing
Shares outstanding
455M
As of Apr 22, 2026
In fiscal 2025 the company spent $200M buying back its own shares and $64M on dividends. Cash actually paid, from its cash-flow statement.
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
3 different filers disclosed GEHC within 90 days. Disclosed 116 days after the transaction; reported as an official range, not an exact amount.
Stock since the trade -0.4% · S&P 500 +2.5% · to Oct 1Traded 23 days after resultsStock 8% above its 52-week low and 27% below its high, after a 12% drop in the previous month
4,363 → 14K shares held+229% of their stake
A board member of GE HealthCare spent $642K of their very own money to buy GE HealthCare shares. 7 other people at GE HealthCare bought some too, in the same month. Their pile of GE HealthCare shares grew by 229%.
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Stock since the trade +2.7% · S&P 500 +3.5% · to Oct 1Traded 13 days after resultsStock within 5% of its 52-week low
0 → 1,618 shares held
A board member of GE HealthCare spent $100K of their very own money to buy GE HealthCare shares. 7 other people at GE HealthCare bought some too, in the same month.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Short sale volume: 61.1% of the volume reported to FINRA over the last 20 trading days was marked short, above its 1-year average of 54.5%. FINRA daily files, to Oct 2, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.
Dodge & Cox
Schedule 13G: passive · filed Aug 7, 2026 · 37.9M shares
Vanguard Capital Management
Schedule 13G: passive · filed Apr 29, 2026 · 33.4M shares
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
Last 12 months, adjusted daily closes
Adjusted close went from $75.51 on Oct 1, 2025 to $63.98 on Oct 1, 2026 (-15.3%). Disclosed trades in the last 12 months: 8 insider purchases, 0 insider sales, 1 Congress purchase, 2 Congress sales. 1 group of purchases by several insiders within a few days.
Top officer leaving
“Grogan’s offer letter provides for an annual base salary of $900,000, target annual bonus opportunity equal to 100% of base salary, an annual long-term incentive (“LTI”) award with a target grant date value of $3,300,000, and participation in GE HealthCare’s benefit plans, including its Retirement Savings Plan, Restoration Plan, and US Severance and Change in Control Plan for CEO and Leadership Te”
8-K on sec.govTop officer leaving
“(Jay) Saccaro notified GE HealthCare that he will resign as Chief Financial Officer for a role outside of the medical technology industry.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
7 certified in FY2026 Q3, vs 17 a year earlier. 7 positions in total, median offered wage $165K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
30 approvals or clearances and 58 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.